Vascular Biogenics (NASDAQ:VBLT) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03), MarketWatch Earnings reports.

Shares of VBLT opened at $1.15 on Wednesday. Vascular Biogenics has a 12-month low of $1.10 and a 12-month high of $8.75. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.45 and a current ratio of 10.45. The stock has a market cap of $40.19 million, a P/E ratio of -3.11 and a beta of -1.25.

VBLT has been the topic of a number of recent analyst reports. HC Wainwright upgraded Vascular Biogenics from a “neutral” rating to a “buy” rating and set a $3.00 price objective on the stock in a research note on Monday, October 15th. Zacks Investment Research upgraded Vascular Biogenics from a “hold” rating to a “buy” rating and set a $1.75 price objective on the stock in a research note on Thursday, August 23rd. Finally, Chardan Capital reiterated a “hold” rating and issued a $3.00 price objective on shares of Vascular Biogenics in a research note on Tuesday. Five equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Vascular Biogenics currently has an average rating of “Hold” and a consensus price target of $2.94.

An institutional investor recently raised its position in Vascular Biogenics stock. Morgan Stanley boosted its position in shares of Vascular Biogenics Ltd (NASDAQ:VBLT) by 305.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 95,560 shares of the biopharmaceutical company’s stock after acquiring an additional 72,000 shares during the period. Morgan Stanley owned approximately 0.27% of Vascular Biogenics worth $155,000 at the end of the most recent quarter. 16.36% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Daily Political and is the property of of Daily Political. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at

Vascular Biogenics Company Profile

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.

Read More: How is the discount rate different from the Federal Funds rate?

Earnings History for Vascular Biogenics (NASDAQ:VBLT)

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with's FREE daily email newsletter.